Maximizing the Likelihood of Closing a Deal This Year

A few months ago, I posted a related article about deal timing titled ‘Maintaining Deal Momentum in the Summer Months’.  Now it is early August, and we are deep in the summer slowdown.  Many of us are enjoying the last stints of our summer holidays before returning to...

What happened to the value of priority review vouchers (PRV)?

The FDA Amendments Act of 2007 created an incentive system for drug developers to pursue tropical neglected diseases, whereby upon approval of a product for a designated tropical disease, the drug developer would receive a voucher that could be applied to receive a...

Immunomedics and venBio: Activist Investors in Biotech

This has certainly been an eventful few months for Immunomedics and its largest shareholder, venBio.  In case you haven’t been following, below is a brief replay: Towards the end of last year, venBio, the beneficial owner of approximately 9.9% of the outstanding...

Business Development  Implications of the 21st Century Cures Act

Last week, both chambers of Congress voted nearly unanimously to pass the 21st Century Cures Act (the Cures Act), sweeping legislation that directly impacts the government funding and FDA review process of medical innovations, both pharmaceutical and device. ...

Implications of the US election on the Life Science Industry

After months of long, hard debate, the votes are in and Donald Trump will become the next president of the United States. The result is one that few had predicted, including the markets. The outcome of this election has been closely watched by professionals within the...